ZeroStack Corp.

ZSTK
About the company

ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany. It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods and medical products to treat various health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. It also operates as a decentralized AI treasury company that invests in the future of AI infrastructure through strategic ownership of 0G tokens.

Country: United StatesPrice: $2.74Market Cap: $59.7M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

2 / 12

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 10 investors flag at least one cash flow criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILPASSFAILFAILFAILFAILPASSFAILFAILFAILNEUTRALNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

TTM ended 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-27

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-27

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-07-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-07-31

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-119.3M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-5.6M
      ✗LynchPositive and growing
      Operating Cash Flow$-8.7M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-6.66%, ROA=-91.94%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-14.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/6 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-83.7%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/6 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-5.6M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-9.33%; #3204/4519 (top 70.9%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -66.6% vs Rev: -23.6%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$-13.68 (2022) -> $-43.49 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-0.5%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency2/3 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 23.3% -> 4.6%, operating margin -66.2% -> -433.5%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR220.2%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag ZSTK's efficiency

      Current Ratio0.95
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-346.0%
      ✗Buffett> 10%
      ROIC - WACC-356.0%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.05 -> 1.01
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY1.37x -> 0.27x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.95
      ✗Dreman> 1.5
      Return on Invested Capital-1165.2%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-477.3%; FY2024: ROIC=-107.0%; FY2025: ROIC=-98.5%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -98.5%)
      ✗SleepROIC > 12% in a majority of years
    • Profitability6% pass✓ 3✗ 32▾

      15 of 16 flag ZSTK's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/8 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/8 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-306.6%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-433.5% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-119.3M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-1287.0%
      ✗Lynch> 15%
      EBIT / Enterprise Value-402.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-402.4%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-91.94%
      ✗PiotroskiROA > 0
      ROA Change YoY-60.65% -> -91.94% (delta: -31.28%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-6.66%, ROA=-91.94%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY6.1% -> 4.6%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-436.1%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-1287.0%
      ✗Dreman> 12%
      Margin of SafetyP/B=0.1x
      ✓PabraiP/B < 1.5 or P/E < 15
      Return on Equity-471.0% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/6 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-598.0%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-1287.0%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-66.2% (2023) -> -433.5% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 23.3% -> 4.6%, operating margin -66.2% -> -433.5%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-297.76%; #5790/6340 (top 91.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+20.88%; #2008/3702 (top 54.2%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-1287.00%; #5177/5226 (top 99.1%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.7540; #5160/5884 (top 87.7%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation8% pass✓ 8✗ 20▾

      12 of 13 flag ZSTK's valuation — Graham, Lynch, Greenblatt +9 more

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio0.1x
      ✓Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-402.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-402.4%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share0.1x
      ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-1790.8%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-14.7%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=0.1x
      ✓MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low100% of trailing low ($2.74)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-297.76%; #5790/6340 (top 91.3%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.2314; #4029/6449 (top 62.5%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share0.09x
      ✓SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+246.1%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.6703; #2257/5247 (top 43.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-9.33%; #3204/4519 (top 70.9%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-47.10%; #5061/6202 (top 81.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Verdicts14% pass✓ 2✗ 12▾

      Split decision: 12 FAIL · 2 PASS · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (3/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 2)✗DremanFAIL (2/11)✓MungerPASS (2/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)✓TempletonPASS (4/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #2348/2370 (Top 99.1%))✗NeffFAIL (1/6)•SchlossNEUTRAL (4/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage42% pass✓ 8✗ 7▾

      7 of 12 flag ZSTK's debt & leverage — Graham, Buffett, Piotroski +4 more

      LT Debt vs Net Current AssetsLT Debt $0.0M vs NCA $-0.6M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.76, IC: -991.4x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0.17
      ✓Lynch< 0.33
      Cash - Long-term Debt$2.6M
      ✓LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 38.98%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.95
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0.17
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0.17
      ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-991.4x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0.17
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.1746; #1587/4210 (top 37.7%)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Wholesale
    SIC Sector: Nondurable Goods Wholesale
    Size: Micro Cap($59.7M)
    Revenue: $35.7M-0.5% YoY
    Net Income: $119.7M-652.7% YoY

    Financial Snapshot

    Operating Margin-433.5%
    Return on Equity-169.7%
    Debt / Equity0.76
    Current Ratio1.01
    EPS (Diluted)$-43.49

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: interest expense, operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-02-27
    FY 2024
    Sources
    • 10-K · 2025-03-24
    FY 2023
    Sources
    • 10-K · 2024-03-28
    FY 2022
    Sources
    • 10-K · 2023-03-31
    FY 2021
    Sources
    • 20-F · 2022-05-09
    Market Cap$59.7Mcurrent----$27.9Mest.$562.4Mest.$385.4Mest.$1.5Best.--
    Revenue$40.0M↓24%$13.7M↓8%$7.3M↓38%$35.7M↓1%$35.9M↓53%$76.1M↑128%$33.4M↑272%$9.0M
    Operating Income-$239.4M↓1718%-$24.2M↓844%-$62.7M↓6313%-$154.7M↓1633%-$8.9M↑82%-$50.4M↓7%-$47.2M↓148%-$19.0M
    Net Income-$177.8M↓1260%-$24.6M↓921%-$36.7M↓4736%-$119.7M↓653%-$15.9M↑72%-$57.0M↓9%-$52.4M↓145%-$21.4M
    EPS (Diluted)--$-2.47↓2145%$-3.68↓9100%$-43.49↓3245%$-1.30↑83%$-7.75↑43%$-13.68--
    Gross Margin13.1%↓39%11.8%↓38%43.2%↑77%4.6%↓25%6.1%↓74%23.3%↓41%39.7%↑47%27.0%
    Operating Margin-598.0%↓2279%-177.4%↓923%-861.3%↓10291%-433.5%↓1642%-24.9%↑62%-66.2%↑53%-141.4%↑33%-211.6%
    ROE-1287.0%↓296%——-169.7%↑52%-352.7%↑60%-890.6%↓866%-92.2%↓233%-27.7%
    Total Debt$2.4M↓22%$2.4M↓22%$3.2M↑27%$53.5M↑2472%$2.1M↑8%$1.9M↑78%$1.1M↓18%$1.3M
    Shareholders' Equity$13.8M↑243%$13.8M↑243%$36.8M↑673%$70.6M↑1464%$4.5M↓30%$6.4M↓89%$56.8M↓26%$77.2M
    Current Ratio0.95↓1%0.95↓1%1.39↑32%1.01↓4%1.05↓20%1.31↓27%1.79↓77%7.84
    Debt / Equity0.17↓77%0.17↓77%0.09↓84%0.76↑64%0.46↑53%0.30↑1478%0.02↑12%0.02
    Operating Cash Flow-$5.5M↑39%$1.4M↑148%-$3.8M↓41%-$8.7M↓72%-$5.0M↑40%-$8.4M↑47%-$15.9M↑24%-$20.9M
    Free Cash Flow-$5.6M↑39%$1.4M↑146%-$3.8M↓40%-$8.8M↓70%-$5.2M↑40%-$8.6M↑50%-$17.2M↑31%-$24.9M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Wholesale

    ZSTK vs Peers — Financial Grading

    Revenue$35.7MBottom 25%
    Net Income$119.7MBottom 25%
    ROE-169.7%Bottom 25%
    D/E0.76Bottom 25%
    Op. Margin-433.5%Bottom 25%
    Curr. Ratio1.01Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    MCKESSON CORPMCK$127.3B$1102.81$403.4B$4.8B-219.2%-3.001.5%0.852/95/94/70/3F-Score 61/11
    W.W. GRAINGER, INC.GWW$69.7B$1489.30$17.9B$1.7B45.7%0.6713.9%2.834/96/94/71/3F-Score 65/11
    CARDINAL HEALTH INCCAH$65.0B$281.10$254.2B$1.7B-59.5%-3.081.0%0.882/93/93/70/3F-Score 81/11
    SYSCO CORPSYY$38.0B$77.10$81.4B$1.8B99.9%—3.8%1.213/95/95/71/3F-Score 42/11
    RELIANCE, INC.RS$21.8B$427.33$14.3B$739.4M10.3%0.207.1%4.884/97/93/70/3F-Score 55/11
    WATSCO INCWSO$12.8B$308.46$7.2B$497.0M17.9%0.1710.0%4.125/97/94/71/3F-Score 68/11
    APPLIED INDUSTRIAL TECHNOLOGIES INCAIT$10.9B$297.60$4.6B$393.0M21.3%0.3110.9%3.326/95/94/71/3F-Score 57/11
    POOL CORPPOOL$7.7B$216.20$5.3B$406.4M34.3%1.0111.0%2.243/96/94/71/3F-Score 56/11